Success Metrics

Clinical Success Rate

55.6%

Based on 5 completed trials

Completion Rate

56%(5/9)

Active Trials

0(0%)

Results Posted

120%(6 trials)

Terminated

4(44%)

Phase Distribution

Ph phase_2

67%

Ph phase_3

22%

Ph phase_1

11%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution9 total trials

Phase 1Safety & dosage

1(11.1%)

Phase 2Efficacy & side effects

6(66.7%)

Phase 3Large-scale testing

2(22.2%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

55.6%

5 of 9 finished

Non-Completion Rate

44.4%

4 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(5)

Terminated(4)

Detailed Status

Completed5

Terminated4

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

55.6%

Most Advanced

Phase 3

Trials by Phase

Phase 11 (11.1%)

Phase 26 (66.7%)

Phase 32 (22.2%)

Trials by Status

completed556%

terminated444%

Recent Activity

0 active trials

Showing 5 of 9

completedphase_1

PK of Serelaxin in Severe Renal Impairment and ESRD

NCT01875523

terminatedphase_3

Efficacy, Safety and Tolerability of Sexelaxin When Added to Standard Therapy in AHF

NCT02007720

completedphase_2

Study of the Vascular Effects of Serelaxin

NCT01979614

terminatedphase_2

Pharmacokinetics & Safety of Serelaxin on Top of Standard of Care Therapy in Pediatric Patients With Acute Heart Failure

NCT02151383

terminatedphase_3

Effect of Serelaxin Versus Standard of Care in Acute Heart Failure (AHF) Patients

NCT02064868

View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials

NCT01875523Phase 1

PK of Serelaxin in Severe Renal Impairment and ESRD

Completed

NCT02007720Phase 3

Efficacy, Safety and Tolerability of Sexelaxin When Added to Standard Therapy in AHF

Terminated

NCT01979614Phase 2

Study of the Vascular Effects of Serelaxin

Completed

NCT02151383Phase 2

Pharmacokinetics & Safety of Serelaxin on Top of Standard of Care Therapy in Pediatric Patients With Acute Heart Failure

Terminated

NCT02064868Phase 3

Effect of Serelaxin Versus Standard of Care in Acute Heart Failure (AHF) Patients

Terminated

NCT02669875Phase 2

Serelaxin To Lower Portal Pressure

Completed

NCT02625922Phase 2

Study of the Effect of Serelaxin on High-sensitivity Cardiac Troponin I (Hs-cTnI) Release in Patients With Chronic Heart Failure

Terminated

NCT02002702Phase 2

Study of Safety, Tolerability and Pharmacokinetics of Serelaxin in Japanese Acute Heart Failure (AHF) Patients

Completed

NCT00259103Phase 2

Recombinant Human Relaxin (rhRlx) in Pregnant Women Scheduled for Induction of Labor

Completed

All 9 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 9